A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.

Trial Details

NCT ID
NCT05669430
Phase
PHASE1 / PHASE2
Sponsor
GV20 Therapeutics
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • GV20-0251
  • GV20-0251 and Pembrolizumab [KEYTRUDA®]
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Denver, Colorado, United States|39.73915,-104.9847
  • New Haven, Connecticut, United States|41.30815,-72.92816
  • Fort Myers, Florida, United States|26.62168,-81.84059
  • Indianapolis, Indiana, United States|39.76838,-86.15804

Key Eligibility Criteria

  • Participants ≥18 years of age
  • Previously treated, histologically-confirmed advanced solid malignancy with progressive disease requiring therapy
  • Refractory or intolerant to standard therapy(ies)
  • Must have received, be not eligible or decline standard of care therapy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →